RegulationPriority Review (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC20H25ClN6O2S

InChIKeyUHYCLWAANUGUMN-SSEXGKCCSA-N

CAS Registry1423719-30-5

Clinical Trials associated with Nerandomilast

NCT07540988

/ Not yet recruitingPhase 3

A Double-blind, Randomized, Placebo-controlled Trial Investigating the Efficacy and Safety of Nerandomilast Over at Least 52 Weeks in Patients With Fibrosing Interstitial Lung Disease at Risk for Disease Progression (FIBRONEER-ACT)

This study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they have been diagnosed with this condition within the last 3 years and are at risk of developing progressive pulmonary fibrosis (PPF). The purpose of this study is to find out whether a medicine called nerandomilast helps people with fibrosing interstitial lung disease who may be at risk for their disease getting worse.
Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Nerandomilast is a type of medicine that may help reduce lung function decline and slow disease progression.
Participants are in the study for up to about 2 years and 4 months. During this time, they visit the study site regularly. Doctors regularly test lung function using methods like spirometry to measure forced vital capacity (FVC, maximum amount of air a participant can blow out after taking a deep breath) and DLCO (diffusing capacity of the lungs for carbon monoxide; it estimates how well oxygen moves from the lungs into the blood). Additionally, high-resolution computed tomography (HRCT) is performed to monitor how the lung condition is changing over time. The results are compared between the groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Start Date28 Aug 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT07366034

/ Not yet recruitingPhase 3

A Study to Evaluate the Dose-exposure, Safety, and Exploratory Efficacy of Nerandomilast in Children and Adolescents From 2 Years to Less Than 18 Years of Age With Fibrosing Interstitial Lung Disease (Part A: Double-blind, Placebo-controlled in Children From 6 to Less Than 18 Years of Age and Open-label Active Treatment in Children From 2 to Less Than 6 Years of Age), Followed by an Open-label Phase With Active Treatment (Part B)

This study is open to children and adolescents aged 2 to 17 years with interstitial lung disease (ILD). Nerandomilast has just been approved in some countries to help adults with a lung condition called idiopathic pulmonary fibrosis. The purpose of this study is to understand how nerandomilast is tolerated and handled by the body and whether nerandomilast also helps children and adolescents with ILD.
For participants aged 6 to 17 years when joining, the study has 2 parts. In the first part, participants are put into 1 of 2 groups randomly, which means by chance. One group gets nerandomilast and the other group placebo. Placebo looks like nerandomilast but does not contain any medicine.
Participants are twice as likely to be in the nerandomilast group. They take tablets twice a day for 6 months. After these 6 months, in the second part of this study, they get nerandomilast for at least 2 years regardless of what they got in the first part.
Young participants aged 2 to 5 years when joining get nerandomilast from the start. They receive tablets twice a day for at least 2 and a half years.
Depending on when a person joins, the study lasts between 2 and a half years and up to 5 years. During this time, participants may visit the study site about 18 to 30 times. Study doctors collect blood samples to check participants' health and to find out how their body handles the study medicine. Doctors also check the function of the lungs, body growth, and how participants feel. The study doctors also regularly check participants' health and take note of any changes. For participants aged 6 to 17 years, the results are compared between the groups to see whether nerandomilast treatment helps children and adolescents.

Start Date27 Jul 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT07321860

/ Not yet recruitingPhase 2/3

Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Partial TGF-βR1 (ALK5) Inhibition With Galunisertib Combined With PDE4 Inhibition With Nerandomilast in GREM2-Positive ALS

Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disorder characterized by loss of upper and lower motor neurons, leading to muscle weakness, respiratory decline, and eventual mortality. A growing body of translational and clinical evidence implicates neuroinflammation, reactive astrocytosis, and maladaptive TGF-β signaling as central contributors to disease progression. Elevated levels of Gremlin-2 (GREM2) have been identified as a marker of dysregulated TGF-β-linked astrocytic activity and fibrotic gene programs in some ALS patients, and preclinical data suggest that attenuating these pathways may mitigate glial toxicity and improve neuronal survival.
Galunisertib, a selective ATP-competitive TGF-β receptor type I (TGF-βR1/ALK5) inhibitor, has been developed to block SMAD2/3 phosphorylation and TGF-β-mediated transcriptional programs. Meanwhile, nerandomilast, a selective PDE4B inhibitor, elevates intracellular cAMP in immune and glial cells, shifting pro-inflammatory signaling toward resolution and antagonizing secondary fibrotic and inflammatory cascades. Preclinical models show that PDE4 inhibition and TGF-β pathway blockade concurrently reduce maladaptive glial phenotypes and fibrotic mediators.
This study investigates the combination of galunisertib + nerandomilast in ALS patients with elevated GREM2, hypothesizing that dual targeting of TGF-β-mediated astrocytic reactivity and PDE4B-regulated inflammatory signaling will translate into slowing of disease progression and favorable pharmacodynamic effects on central biomarkers of neuroinflammation and neurodegeneration.

Start Date30 Jun 2026

Sponsor / Collaborator-

100 Clinical Results associated with Nerandomilast

100 Translational Medicine associated with Nerandomilast

100 Patents (Medical) associated with Nerandomilast

Literatures (Medical) associated with Nerandomilast

01 Apr 2026·British Journal of Pharmacology

Nerandomilast, a PDE4B inhibitor, alleviates silica‐induced lung inflammation and fibrosis by inhibition of NLRP3 inflammasome and TGF‐β/Smad signalling

Article

Author: Song, Yawen ; Wang, Yuanying ; Ye, Qiao ; Sun, Di ; Dilixiati, Nafeisa ; Wang, Dongmei

Background and Purpose:

Silicosis is a major cause of occupational disease‐related morbidity and mortality worldwide, yet effective pharmacological treatments remain limited. Nerandomilast, a novel inhibitor of phosphodiesterase‐4B (PDE4B), has demonstrated anti‐fibrotic potential in idiopathic pulmonary fibrosis (IPF); however, its efficacy and mechanisms in silicosis have not been investigated.

Experimental Approach:

The therapeutic effects (and their underlying mechanisms) of PDE4B inhibition was evaluated in in models of silicosis, both in vivo (male C57BL/6N mice) and in vitro (THP‐1 macrophages and MRC‐5 cells). Single‐cell RNA sequencing, using lung tissue, was first performed to identify PDE4B as a key regulatory target in the pathogenesis of silicosis. Based on this finding, the therapeutic effects and underlying mechanisms of PDE4B inhibition were assessed using nerandomilast. Pulmonary function tests, inflammatory marker analyses and fibrosis evaluations were conducted to determine treatment efficacy. In addition, bulk RNA sequencing and transcriptomic analyses were performed to explore the molecular pathways modulated by nerandomilast.

Key Results:

PDE4B inhibition effectively prevented and attenuated silica‐induced lung inflammation in the mouse model by suppressing both canonical and non‐canonical NLRP3 inflammasome pathways in lung macrophages. Furthermore, PDE4B inhibition down‐regulated TGF‐β/Smad signalling in lung fibroblasts of silicosis, leading to a significant reduction in fibrosis‐related gene expression.

Conclusions and Implications:

These findings suggest that nerandomilast, a PDE4B inhibitor, may be a promising treatment for silicosis, which currently lacks effective therapies.

01 Mar 2026·Clinical Respiratory Journal

Safety and Efficacy of Nerandomilast in Patients With Pulmonary Fibrosis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Review

Author: Nawaz, Ahmad ; Alsubari, Asma'a Munasar Ali ; Ehsan, Muhammad ; Shahzad, Humna ; Jafar, Uzair ; Komminni, Praveen Kumar ; Thummar, Freya ; Irfan, Rafay ; Saleem, Fahad ; Murtaza, Hafiz Nadir ; Nadeem, Ahmed ; Afzaal, Usama ; Gul, Ahmad Hassan ; Gelan, Abel ; Ahsan, Maria ; Iribarren, Juan

ABSTRACT:

Objective:

Nerandomilast, an oral phosphodiesterase‐4 (PDE4) inhibitor, has shown potential in slowing the progression of pulmonary fibrosis. This meta‐analysis evaluated the efficacy and safety of nerandomilast in preserving lung function among patients with pulmonary fibrosis.

Methods:

MEDLINE, Embase, the Cochrane Library, and ClinicalTrials.gov were systematically searched for randomized controlled trials (RCTs) comparing nerandomilast with placebo. Study quality was assessed using the Cochrane Risk of Bias 2.0 tool. Analyses were performed in RevMan 5.4 using random‐effects models with risk ratios (RR) and mean differences (MD) as effect measures.

Results:

Four RCTs ( n = 2515) were included. Nerandomilast significantly attenuated the decline in forced vital capacity (FVC) compared with placebo (MD: 69.25 mL, 95% CI: 52.1–86.29), but did not improve diffusing capacity for carbon monoxide (DLCO) (MD: 0.84, 95% CI: −0.56 to 2.24). It was associated with a lower pooled risk of all‐cause mortality (RR: 0.68, 95% CI: 0.52–0.88) without increasing adverse events (RR: 1.00, 95% CI: 0.98–1.02) or serious adverse events (RR: 0.93, 95% CI: 0.76–1.14).

Conclusion:

Nerandomilast appears to slow lung function decline in pulmonary fibrosis without added safety risks. Although a lower pooled risk of mortality was observed, individual trials were not powered for mortality outcomes, and event rates were low; therefore, this finding should be interpreted cautiously. Given the heterogeneity of pulmonary fibrosis phenotypes and trial designs, further large‐scale RCTs should explore standardized outcomes, subgroup effects, and combination strategies with nintedanib or pirfenidone.

01 Jan 2026·European Respiratory Review

Mechanistic basis for the antifibrotic actions of cAMP-based therapies

Review

Author: Fortier, Sean M ; Peters-Golden, Marc

The human and economic impact of idiopathic pulmonary fibrosis and other interstitial lung diseases is enormous, and available therapies are of limited utility. A decade after the introduction of the first antifibrotic agents, two new agents are on the horizon. Nerandomilast is an inhibitor of phosphodiesterase 4B, while treprostinil is an analogue of prostacyclin. Both agents increase intracellular cAMP. Although the smooth muscle relaxant properties of agents that increase cAMP have long been leveraged for the treatment of airway and vascular diseases, potential antifibrotic actions of cAMP elevation are much less well appreciated by clinicians and researchers. The purpose of this review is to discuss the mechanistic underpinnings for a beneficial role of cAMP in fibrotic lung diseases. We briefly review the pathogenesis of fibrotic lung disease, the anatomy of the cAMP pathway, and the myriad ways in which this pathway is disrupted in fibrotic diseases. We then focus on the pleiotropic actions by which cAMP opposes the aberrant phenotypes of immune cells, fibroblasts, and epithelial cells that characterise fibrotic diseases. Finally, we highlight some unanswered questions about, and future opportunities for optimising, therapeutic interventions that leverage the cAMP pathway.

News (Medical) associated with Nerandomilast

29 Apr 2026

·www.biopharmadive.com

Avalyn, in pursuit of better lung drugs, banks $300M in an IPO

Dive Brief:Avalyn Pharma on Wednesday raised $300 million in a large initial public offering thatll support development of a portfolio of drugs for hard-to-treat lung diseases.The Boston biotechnology company priced 16.7 million shares at $18 each, significantly exceedingthe roughly $200 million target it had originally set. Avalyn will begin trading Thursday on the Nasdaq stock exchange under the ticker symbol AVLN.Avalyns offering is the eighth for a young drugmakerin 2026. Those startups have secured a median of $309 million in IPO proceeds, a spike in value compared to previous years that some investors believe will open up opportunities for a broader array of biotech companies.Dive Insight:Avalyn is developing treatments for the progressive and idiopathic forms of pulmonary fibrosis, a rare condition where progressive lung scarring causes difficulty breathing, a decline in organ function and eventually death. According to the company, an estimated 300,000 people in the U.S. have some type of pulmonary fibrosis. They have three marketed medicines that can help manage their symptoms: Ofev, Esbriet and Jascayd.Esbriet, which Roche won approval for more than a decade ago, prevents scar tissue from building up. Ofev, which is made by Boehringer Ingelheim, blocks some of the cell-surface receptors linked to fibrosis. Jascayd, also from Boehringer, slows the decline of lung function by acting on a different target. Those drugs dont stop the disease altogether,though, and have tolerability issues, leaving an opportunity for young biotechs like Avalyn to capitalize on.Avalyn is making inhalable versions of Ofev and Esbriet that it expects will prove more potent and easier to use. One drug, AP01, is in a Phase 2b trial in progressive pulmonary fibrosis. Another, AP02, is in a mid-stage study in the idiopathic form of the disease.Avalyn expects to present topline data from both of those trials by the end of 2027.A third experimental prospect,AP03, combines Ofev and Esbriet and is set to enter a Phase 1 trial by the end of the year. Avalyn claimed in its IPO prospectus that these specialized, inhalable formulations represent a more reliable and patient-friendly solution for the condition.Avalyn is one of many companies working on newer pulmonary fibrosis drugs, however. Positive late-stage results have positioned United Therapeuticsto seek approval of its already-marketed medicine, Tyvaso, in idiopathic disease later this year. That form of the condition is also the target of drugs in development at Bristol Myers Squibb, Contineum Therapeutics and startup Celea Therapeutics. The market for idiopathic pulmonary fibrosis drugs could be worth as much as $5.8 billion by 2034, according to analytics firm GlobalData.The pace of IPOs in 2026 has, so far, been similar to the slower-than-usual trajectory the sector has experienced over the last five years. Still, two other biotechs brain drug developer Seaport Therapeutics and blood cancer specialist Hemab Therapeutics could price offerings this week. '

IPOPhase 1Drug ApprovalPhase 2

09 Apr 2026

·firstwordpharma.com

Avalyn and its inhaled lung disease hopefuls join the IPO queue

With 2026 biotech IPOs set to far outpace last year's rate of public debuts, another hopeful has thrown its hat in the ring. Avalyn Pharma lined up this week to make its run at the IPO window, backed with at least $310 million in private funding and a pipeline of inhaled programmes to treat fibrosisThe drugmaker joins obesity-focused Kailera Therapeutics in the IPO queue, following the successful debuts of six companies across January and February. However, the cohort's post-IPO stock performances have been a mixed bag; Generate:Biomedicines, which had the largest raise at $400 million, is down more than 25%, as are Agomab Therapeutics and Eikon Therapeutics (see – Vital Signs: Technologies to watch from the latest newco pool).Inhaled aspirations Avalyn is developing inhaled products to overcome some of the downsides of oral antifibrotic therapies used to treat pulmonary fibrosis, which it said can slow, but not halt or reverse disease progression. Plus, they are associated with gastrointestinal side effects and other toxicities that can interrupt treatment or lead to permanent discontinuations. There are currently three approved such treatments for pulmonary fibrosis: Esbriet (pirfenidone) developed by Roche, and Boehringer Ingelheim's Ofev (nintedanib) and Jascayd (nerandomilast).According to the biotech, about 30% of patients with idiopathic pulmonary fibrosis (IPF) are treated with antifibrotics, and half stop treatment within a year due to side effects. "We believe we may be able to address these limitations through the development of optimised inhaled formulations of these established oral antifibrotic agents," the company said in its IPO prospectus. Avalyn's lead candidate is AP01, an inhaled formulation of pirfenidone for progressive pulmonary fibrosis (PPF). The drugmaker is studying the asset in the Phase IIb MIST trial, and last year teamed up with image analytics firm Qureight to help measure efficacy. Enrollment in MIST should wrap mid-year, and topline data are due in the second half of 2027.The company's second programme, AP02, is in the Phase II AURA study for IPF, with enrollment planned to finish in the second half of 2027 and topline data due later that year. The experimental treatment is an inhaled formulation of nintedanib. AP03, Avalyn's third asset, is a fixed-dose combination of the active ingredients in the first two programmes. A Phase I trial is slated to start in late 2026, with topline data to read out in the second half of 2027.

Phase 2IPOPhase 1

09 Apr 2026

·www.biopharmadive.com

Chasing a tough-to-treat lung disease, Avalyn plans an IPO

Avalyn Pharma, a Boston biotechnology firm testing drugs against a tricky lung condition, revealed Wednesday its plans to go public.Avalyn is making experimental medicines for idiopathic pulmonary fibrosis, or IPF, a rare condition that causes progressive lung scarring, difficulty breathing and other serious health problems. An estimated 100,000 people in the U.S. have IPF, which can be managed by three approved medicines: Ofev, Esbriet, and, more recently,Jascayd.All three treatments slow the disease in one way or another. Roches Esbriet, which hit the market more than a decade ago,helps prevent the buildup of scar tissue.Ofev, made by Boehringer Ingelheim, blocks certain cell-surface receptors implicated in fibrosis. Boehringer also makes Jascayd, which was approved last year and acts on a different target than Ofev.Still, Avalyn noted in its IPO filing that all three options dont stop disease progression entirely and are limited by tolerability challenges associated with being taken orally. Avalyn is hoping to show that inhalable formulations of Ofev and Esbriet that it has developed will prove more effective and easier to take. Those drugs, codenamedAP01 and AP02,are in mid-stage testing. Data are expected by the end of 2027.A third inhalable drug candidate that combines Ofev and Esbriet is in preclinical testing.Avalyn expects to launch an early study in humans by the end of the year.Success against IPF has been difficult to achieve.Multiple drugmakersworking on new treatments have run into clinical setbacksover the years and, upon its approval, Jascayd was described by Leerink Partners' Faisal Khurshid as a modest advance over existing treatments. But Ofev and Esbriet are both blockbusters, proving there are significant financial rewards available to those that can break through. Several are trying, among them Avalyn,Bristol Myers Squibb, AbbVie and United Therapeutics.As of the end of 2025, Avalyn held $138 million in cash and cash equivalents, according to a securities filing. Previously known as Genoa Therapeutics, the company has raised more than $370 million in capital across four venture rounds, backed by a bevy of investors including Norwest Venture Partners, F-Prime Capital, Perceptive Xontogeny Venture Funds and SR One. Novo Holdings is its largest backer, owning just over 13% of company shares.Biotech IPOs have continued at a slow but steady clip in 2026, matching the pace of new stock offerings from the last two years. But the median value of offerings has soared, hovering just over $287 million in 2026, compared to less than half that in the first quarters of 2024 and 2025.With two drugs deep into clinical development, Avalynis also testing a well-established blueprint for IPO success in recent years. More than two-thirds of biotechs that have priced an IPO since 2022 have had at least one drug in or past mid-stage testing at the time of their offering, according to BioPharma Dive data. '

Drug ApprovalIPO

100 Deals associated with Nerandomilast

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Progressive pulmonary fibrosis	China	Boehringer Ingelheim International GmbH	09 Dec 2025
Idiopathic Pulmonary Fibrosis	United States	Boehringer Ingelheim Pharmaceuticals, Inc.	07 Oct 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
CREST Syndrome	Phase 3	United States	Boehringer Ingelheim GmbH	09 Jun 2026
CREST Syndrome	Phase 3	China	Boehringer Ingelheim GmbH	09 Jun 2026
CREST Syndrome	Phase 3	Japan	Boehringer Ingelheim GmbH	09 Jun 2026
CREST Syndrome	Phase 3	Argentina	Boehringer Ingelheim GmbH	09 Jun 2026
CREST Syndrome	Phase 3	Australia	Boehringer Ingelheim GmbH	09 Jun 2026
CREST Syndrome	Phase 3	Austria	Boehringer Ingelheim GmbH	09 Jun 2026
CREST Syndrome	Phase 3	Belgium	Boehringer Ingelheim GmbH	09 Jun 2026
CREST Syndrome	Phase 3	Brazil	Boehringer Ingelheim GmbH	09 Jun 2026
CREST Syndrome	Phase 3	Bulgaria	Boehringer Ingelheim GmbH	09 Jun 2026
CREST Syndrome	Phase 3	Canada	Boehringer Ingelheim GmbH	09 Jun 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05321082 (FIBRONEER-ILD, CTgov)	Phase 3	Progressive fibrotic interstitial lung disease	1,178	Placebo (Placebo)	vfzanqvjzs(rcjhtxdpfj) = pkoxyugxoi vucpfjqgaf (oxdpzatejn, bmednxnxap - cemojkqmyy) View more	-	09 Jan 2026
				BI 1015550 (Nerandomilast 9 mg)	vfzanqvjzs(rcjhtxdpfj) = ceimckkenm vucpfjqgaf (oxdpzatejn, yhmrlwiego - uyoqspdzvk) View more
NCT06624072 (CTgov)	Phase 1	-	15	Nerandomilast (Nerandomilast 18 mg Pediatric (Ped) Fasted State (Treatment T1))	mhigjbjtrr(pqgxjtconl) = dmimsjjjkc mnfhqcmcbw (wnedjbluip, NA) View more	-	08 Jan 2026
				Nerandomilast (Nerandomilast 18 mg Adult Fasted State (Reference R))	mhigjbjtrr(pqgxjtconl) = nvgpposllg mnfhqcmcbw (wnedjbluip, NA) View more
NCT06070610 (CTgov)	Phase 1	-	14	Pirfenidone+Nintedanib (Pirfenidone/Nintedanib alone (Reference))	qrqphuxqlg(jitdcgjalv) = rppnegmvfy urnfuctjio (fguygioese, NA) View more	-	02 Dec 2025
				Pirfenidone+Nerandomilast+Nintedanib (Pirfenidone/Nintedanib in combination with Nerandomilast (Test))	qrqphuxqlg(jitdcgjalv) = niuvoppjkc urnfuctjio (fguygioese, NA) View more
NCT06415045 (CTgov)	Phase 1	-	18	Nerandomilast (Nerandomilast fasted state (Reference (R)))	dxxswrggjc(pwgkaygwda) = geuvcukrio ogjsjeasnp (jsgvbbqkfb, NA) View more	-	01 Dec 2025
				Nerandomilast (Nerandomilast fed state (Test (T)))	dxxswrggjc(pwgkaygwda) = hbwmmdexfc ogjsjeasnp (jsgvbbqkfb, NA) View more
NCT06139302 (CTgov)	Phase 1	-	12	Nerandomilast (Nerandomilast 9 mg)	cdajkdrhos(otlczbfsyo) = lavktxncis dugljqpkfc (nlpmlratza, 13.8) View more	-	01 Dec 2025
				Nerandomilast (Nerandomilast 18 mg)	cdajkdrhos(otlczbfsyo) = zeghmafvnu dugljqpkfc (nlpmlratza, 52.8) View more
NCT06393127 (CTgov)	Phase 1	-	64	nerandomilast (Test treatment (T))	bvoqpmobmi(cuayutmqsi) = lrzzxxmvot lrzzhzyifx (hijlkiwmmp, NA) View more	-	01 Dec 2025
				nerandomilast (Reference treatment (R))	bvoqpmobmi(cuayutmqsi) = dvguquyfqa lrzzhzyifx (hijlkiwmmp, NA) View more
NCT06408870 (CTgov)	Phase 1	-	64	BI 1015550 (BI 1015550 Formulation C1 (Reference, R))	bsdjesbgjy(chrwohmuil) = jhyhnhbkxh qwlrillxfa (wetjaxgcay, na) View more	-	01 Dec 2025
				BI 1015550 (BI 1015550 Formulation C2 (Test, T))	bsdjesbgjy(chrwohmuil) = vyvjnyzxms qwlrillxfa (wetjaxgcay, na) View more
NCT05550636 (CTgov)	Phase 1	-	15	Midazolam (Midazolam (R))	wmvfjqmzkt(lyqvqodzhn) = fopanwnatu ysnttenzqj (iwlwddmwvd, NA) View more	-	01 Dec 2025
				Midazolam (T+BI 1015550 (BI 1015550 + Midazolam (T))	wmvfjqmzkt(lyqvqodzhn) = rzqahnbzbc ysnttenzqj (iwlwddmwvd, NA) View more
NCT05707403 (CTgov)	Phase 1	-	8	R-BI 1015550 (R-BI 1015550 18 mg tablet (T))	colnfgibyc(fxazosyfzr) = dkctqufzlm vbbadqtrfe (mpfwalftlm, 1.07) View more	-	28 Nov 2025
				14C-R-BI 1015550 (14C-R-BI 1015550 10 μg i.v. (R))	colnfgibyc(fxazosyfzr) = nhoazcrhld vbbadqtrfe (mpfwalftlm, 1.07) View more
NCT03422068 (CTgov)	Phase 1	Idiopathic Pulmonary Fibrosis	15	BI 1015550 (18 mg BI 1015550)	rersbhtuif = awgxmjlawl ljcqmqyacj (evhixgdpqr, xuuhbjpewr - mkzztfibil) View more	-	28 Nov 2025
				Placebo (Placebo)	rersbhtuif = qxyqtmhgaq ljcqmqyacj (evhixgdpqr, tugqzzpczy - zyjeueaaka) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Nerandomilast

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation